Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant adebrelimab plus platinum–etoposide in limited-stage small cell lung cancer
ChiCTR2300074591Phase 4Completed
- Sponsor
- Lung Cancer Center, West China Hospital, Sichuan University
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Lung Cancer Center, West China Hospital, Sichuan University. Primary endpoint: Pathological complete response rate. Started Aug 2023; status: completed.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300074591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074591.